Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma

Published:2015-12-08 Issue:1 Volume:77 Page:35-41
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Yanagimoto Hiroaki,Satoi Sohei,Sho Masayuki,Akahori Takahiro,Yamamoto Tomohisa,Hirooka Satoshi,Yamaki So,Kotsuka Masaya,Ryota Hironori,Kinoshita Shoichi,Nishiwada Satoshi,Nagai Minako,Ikeda Naoya,Tsuta Koji,Nakajima Yoshiyuki,Kon Masanori

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2928-z.pdf

Reference17 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

2. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

3. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotnib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

4. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703

5. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure;Medical Oncology;2024-07-05

2. Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma;Pancreatology;2023-12

3. Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy;Internal Medicine;2023-10-01

4. Significance of multiple tumor markers measurements in conversion surgery for unresectable locally advanced pancreatic cancer;Pancreatology;2023-09

5. Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer;Therapeutic Advances in Medical Oncology;2023-01